# Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005

> **NCT05779241** · PHASE3 · COMPLETED · sponsor: **Lyndra Inc.** · enrollment: 83 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder

## Interventions

- **DRUG:** LYN-005
- **DRUG:** Risperidone

## Key facts

- **NCT ID:** NCT05779241
- **Lead sponsor:** Lyndra Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-13
- **Primary completion:** 2023-11-03
- **Final completion:** 2023-12-01
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2024-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05779241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05779241, "Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05779241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*